Multiple tumor immune phenotypes (PD-1 or PD-L1 expression), somatic genomic characteristics (mutational burden and microsatellite instability), the gut microbiome (207), and the HLA class I genotype (208) have all been proposed as predictors of responses to checkpoint inhibitors. This evidence concerns the gene CD274 and neoplasm.